Retrospective analysis of the treatment of BRCA1 and BRCA2 mutation carriers – the experience of a single-center tertiary institution

This is the authors' abstract. We don't add key points for this paper.

Introduction. Breast cancer gene 1 and 2 ( BRCA1 / 2 ) mutation carriers are at a higher risk of developing breast cancer. There are several established risk-reducing therapies. Our study aimed to characterize the BRCA1/2 mutation carriers, and to evaluate the implemented treatment methods. Material and methods. A retrospective analysis of clinical records of 96 female patients hospitalized from October 2019 to December 2022 in the Breast Cancer Unit in Lodz, Poland. Results. Out of 85 BRCA1 and 11 BRCA2 mutation carriers, 96.88% received nipple-sparing or skin-sparing, unilateral or bilateral risk-reducing mastectomies. Out of all the patients, 36 developed 38 breast cancers. One patient was diagnosed with breast cancer 2 years after a bilateral risk-reducing mastectomy. The most common breast cancer subtype was triple-negative breast cancer (73.68%). The patients could receive surgery, chemotherapy, endocrine therapy and radio­therapy. 18 patients had neoadjuvant chemotherapy, in 6 of these patients a complete pathological response (ypT0N0) was achieved. Conclusions. Oncoplastic bilateral risk-reducing mastectomies are effective and safe procedures.